These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 24597345)

  • 1. [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
    Osera S; Yoshino T
    Nihon Rinsho; 2014 Jan; 72(1):29-34. PubMed ID: 24597345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
    Soeda H; Shimodaira H; Ishioka C
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
    Okada Y; Miyamoto H; Goji T; Takayama T
    Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
    Berg M; Soreide K
    Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
    Yarom N; Jonker DJ
    Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
    Troiani T; Zappavigna S; Martinelli E; Addeo SR; Stiuso P; Ciardiello F; Caraglia M
    Expert Opin Biol Ther; 2013 Feb; 13(2):241-55. PubMed ID: 23281932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.
    Heinemann V; Douillard JY; Ducreux M; Peeters M
    Cancer Treat Rev; 2013 Oct; 39(6):592-601. PubMed ID: 23375249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
    De Mattia E; Cecchin E; Toffoli G
    Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular predictors of response to chemotherapy in colorectal cancer.
    Dienstmann R; Vilar E; Tabernero J
    Cancer J; 2011; 17(2):114-26. PubMed ID: 21427555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized treatment for patients with colorectal cancer: role of biomarkers.
    Duffy MJ
    Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways.
    García-Roman S; Garzón-Ibáñez M; Bertrán-Alamillo J; Jordana-Ariza N; Giménez-Capitán A; García-Peláez B; Vives-Usano M; Codony-Servat J; d'Hondt E; Rosell R; Molina-Vila MÁ
    Transl Oncol; 2024 Feb; 40():101878. PubMed ID: 38183801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.
    Moorcraft SY; Smyth EC; Cunningham D
    Therap Adv Gastroenterol; 2013 Sep; 6(5):381-95. PubMed ID: 24003339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platycodin D sensitizes
    Liu Y; Tian S; Yi B; Feng Z; Chu T; Liu J; Zhang C; Zhang S; Wang Y
    Front Oncol; 2022; 12():1046143. PubMed ID: 36387129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target.
    Salvatore L; Calegari MA; Loupakis F; Fassan M; Di Stefano B; Bensi M; Bria E; Tortora G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relating biomarkers to efficacy and the efficacy curve: a review of EGFR therapies in oncology.
    Stroupe SD; Colpitts TL
    Per Med; 2010 Jan; 7(1):19-31. PubMed ID: 29783375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.